An interventional study of exercise and diet restriction and diet restriction in Psoriasis and Polycystic Ovary Syndrome, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to female participants aged 35 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-12-17.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Psoriasis by Cairo University — 6 open to participants now, 6 under way, 1 of them phase 3. Psoriasis · Cairo University.
Among the 22 studies in Psoriasis by Cairo University, this one is the 7th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 with no phase, and was the 16th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →6 of the 22 studies in Psoriasis by Cairo University are open now, in 1 country. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 45–55
Cairo University
Cairo University · Sites in Egypt
Ages 18+
Cairo University · Sites in Egypt
Ages 18–60
Cairo University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 35 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 2 · Phase 4 4
First in 2010; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 40 across the 20 interventional studies, 214 across the 2 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
3 of the studies in Psoriasis by Cairo University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07892339Phase 3Cairo UniversityEfficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis. | 2026-12-13 |
| NCT07919873Cairo UniversityEfficacy of Fractional Co2 Laser With Topical Tacrolimus 0.1 in the Treatment of Nail Psoriasis | 2027-02 |
| NCT07713212Cairo UniversityCombined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis | 2027-02-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies in Psoriasis by Cairo University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Women with psoriasis usually develop many complications including polysyctic ovarian syndrome (PCOS). Nowdays, diet restriction combimed with phsyical exercises may improve both problems
Forty Women with psoriasis with PCOS will be enrolled to be catogrized to Group I or group II. Group I will enroll twenty females with PCOS and Psoriasis who will apply forty minutes walking on treadmill three times per week. Also Group I will follow low calorie diet and daily metformin for 12 weeks. Group II will will enroll twenty females with PCOS and Psoriasis who will follow low calorie diet and daily metformin for 12 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Group I will enroll twenty females with PCOS and Psoriasis who will apply forty minutes walking on treadmill three times per week. Also Group I will follow low calorie diet and daily metformin for 12 weeks.
Behavioral: exercise and diet restriction
Group II will will enroll twenty females with PCOS and Psoriasis who will follow low calorie diet and daily metformin for 12 weeks
Behavioral: diet restriction
Group I will enroll twenty females with PCOS and Psoriasis who will apply forty minutes walking on treadmill three times per week for 12 weeks. Also Group I will follow low calorie diet and daily metformin for 12 weeks.
Group II will will enroll twenty females with PCOS and Psoriasis who will follow low calorie diet and daily metformin for 12 weeks
Psoariasis area and severity index
is an index used to express the severity of psoriasis. It combines the severity (erythema, induration and desquamation) and percentage of affected area
Time frame: it will be measured after 12 weeks
body mass index
it will be assessed after emptying bladder and bowel
Time frame: It will be measured after 12 weeks
waist circumference
it will be measured at level of ambilicus
Time frame: It will be measured after 12 weeks
waist hip ratio
it will be assessed after dividing waist circumference on hip circumference
Time frame: It will be measured after 12 weeks
testesterone
it will be assessed in serum
Time frame: it will be measured after 12 weeks
ratio of luteinizing hormone and follicle-stimulating hormone
it is anindicator on function of sex hormones
Time frame: It will be measured after 12 weeks
Dehydroepiandrosterone
it will be assessed in plasma
Time frame: It will be measured after 12 weeks
Dermatology life Quality Index
it assess impact of skin disease on quality of life
Time frame: It will be measured after 12 weeks
insuiln
it will be assessed in plasma
Time frame: It will be measured after 12 weeks
fasting blood glucose
it will be assessed in plasma
Time frame: It will be measured after 12 weeks
HOMA-IR
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is classically considered to be a good insulin resistance (IR) index
Time frame: It will be measured after 12 weeks
triglycerides
it will be assessed in plasma
Time frame: It will be measured after 12 weeks
total cholesterol
it will be assessed in plasma
Time frame: It will be measured after 12 weeks
high density lipoprotein
it will be assessed in plasma
Time frame: It will be measured after 12 weeks
low density lipoprotein
it will be assessed in plasma
Time frame: It will be measured after 12 weeks
systolic blood pressure
it will be assessed via manual sphygmmanometer
Time frame: It will be measured after 12 weeks
diatolic blood pressure
it will be assessed via manual sphygmmanometer
Time frame: It will be measured after 12 weeks
Started Oct 2025 (actual). Primary completion is estimated for May 2026, 7 months after the start.
Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 7 months is below that.
Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.